4SC: Landmark RESMAIN study data presented at the 5th World Congress of Cutaneous Lymphomas
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
4SC AG (4SC, FSE Prime Standard: VSC) today announced that more than 80% of the events required to unblind the pivotal R…
4SC AG (4SC, FSE Prime Standard: VSC) today announced the results of a scheduled review of 4SC’s program for the clinica…
4SC AG (4SC, FSE Prime Standard: VSC) today provided a business update for the three months ended 30 September 2021, as…
Die 4SC AG (4SC, FSE Prime Standard: VSC) hat heute Informationen zum Geschäftsverlauf der vergangenen drei Monate zum 3…
First Patient Enrolled in TURANDOT Study Evaluating Domatinostat in the Neoadjuvant Setting in Urothelial Carcinoma Comb…
. - MERKLIN1 study progress update - EMERGE phase IIa clinical data presentation - DONIMI phase Ib clinical data presen…
. - MERKLIN 1 Update zum Studienfortschritt - EMERGE Phase IIa Präsentation klinischer Daten - DONIMI Phase Ib Präsenta…
* MERKLIN1: Trial in progress e-poster (ID 123) and oral presentation entitled "A phase II, open label, multicenter stud…
4SC today announced the initiation of a second clinical collaboration with the Netherlands Cancer Institute (NKI) on a p…